He Q. Tafazzin knockdown causes hypertrophy of neonatal ventricular myocytes. Am J Physiol Heart Circ Physiol 299: H210-H216, 2010. First published March 26, 2010 doi:10.1152/ajpheart.00098.2010.-Mutation of the mitochondrial protein tafazzin causes dilated cardiomyopathy in Barth syndrome. We employed an adenovirus as a vector to transfer tafazzin small hairpin RNA (shRNA) into neonatal ventricular myocytes (NVMs) to investigate the effects of tafazzin knockdown. The tafazzin shRNA adenovirus consistently knocked down tafazzin mRNA and lowered cardiolipin while significantly decreasing the production of ATP by the mitochondria. The phosphorylation of AMP-activated protein kinase and mitochondrial density were both increased in tafazzin knockdown NVMs compared with scrambled shRNA controls. When we tested whether tafazzin knockdown causes hypertrophy in vitro, we found that the surface area of NVMs infected with tafazzin shRNA adenovirus was significantly increased, as were the protein synthesis and expression of the hypertrophic marker gene, brain natriuretic peptide. Taken together, our data support the concept that a decreased tafazzin expression causes cardiomyocyte hypertrophy in vitro.
TAFAZZIN IS A MITOCHONDRIAL protein encoded by the G4.5 gene in humans (7) . It is a phospholipid transacylase (54) , and its mutation results in decreased cardiolipin (18, (47) (48) (49) 53) , a phospholipid predominantly present in the inner membrane of the mitochondria. Cardiolipin is initially synthesized as a premature form, which is deacylated by a phospholipase to generate monolysocardiolipin, and this lipid is finally reacylated by tafazzin to form the mature fully functional cardiolipin (17, 54) . Cardiolipin is required for 1) optimal activity of respiratory chain complexes and ADP-ATP translocase (31) , which are involved in ATP and reactive oxygen species production; 2) cytochrome c attachment within the mitochondrial intermembrane space (39) , which is associated with mitochondria-initiated cell death; 3) maintaining inner membrane fluidity and osmotic stability (11) , which are associated with the opening of mitochondrial permeability transition pores and mitochondria-gated cell death; and 4) mitochondrial protein import (30) , which is associated with mitochondrial biogenesis.
Tafazzin mutation causes Barth syndrome, a rare X-linked genetic disorder characterized by dilated cardiomyopathy (DCM) with or without hypertrophy, skeletal myopathy, neutropenia, growth retardation, and 3-methylglutaconic aciduria (4, 5, 45) . End-stage heart failure resulting from DCM is a major cause of death among these patients during infancy and early childhood.
DCM, the most common type of cardiomyopathy, is characterized by ventricular chamber enlargement and systolic dysfunction, commonly resulting in congestive heart failure (35) . An eccentric cardiomyocyte hypertrophy (increased length-to-width ratio) and an energy depletion are characteristic of DCM (15, 20, 21, 36) .
A deletion of tafazzin in yeast causes mitochondrial dysfunction, including changes in energy transformation and osmotic properties of the mitochondria (18, 34) . A mutation of tafazzin in Drosophila causes a pathological dysfunction of mitochondria and motor weakness (53) . Tafazzin knockdown in zebrafish led to bradycardia and retarded cardiac development (32) . The decreased expression of tafazzin has been shown in spontaneously hypertensive failing hearts (42) . However, we do not know how tafazzin knockdown affects mammalian cardiomyocytes. We here present evidence that tafazzin knockdown results in ATP deficiency and hypertrophy in cultured neonatal cardiomyocytes.
METHODS
All animal experiments were approved by the Henry Ford Health System Institutional Animal Care and Use Committee.
Supplies and chemicals. Phosphatase and proteinase inhibitor cocktail tablets (PhosSTOP and Complete Mini) were obtained from Roche Applied Science (Indianapolis, IN). A pSilencer adeno 1.0-CMV system was purchased from Ambion (Austin, TX). Primary antibodies against phospho-AMP-activated protein kinase (phospho-AMPK) (Thr172) and AMPK and an horseradish peroxidase-conjugated secondary antibody against rabbit IgG were obtained from Cell Signaling Technology (Boston, MA). ␤-Actin antibody and FITCconjugated anti-goat IgG were purchased from Santa Cruz (Santa Cruz, CA). Coomassie protein assay and SuperSignal West Pico chemiluminescent substrate kits and Restore Plus Western blot stripping buffer were purchased from Thermo Scientific (Rockford, IL). MitoTracker Red, Taq DNA polymerase kits, DMEM medium and cell culture supplements, precast Tris-glycine polyacrylamide gels, and polyvinylidene fluoride membranes were obtained from Invitrogen (San Diego, CA). Laminin-coated coverslips were purchased from BD Sciences (San Jose, CA). ATP bioluminescent assay kits and 4,6-diamidino-2-phenylindole (DAPI) were obtained from Sigma (St. Louis, MO). [ 32 P]phosphate and [ 3 H]leucine were purchased from PerkinElmer (Waltham, MA); Whatman TLC plates (LK5D silica gel, 150 Å) were from VWR (Batavia, IL); RNeasy fibrous tissue mini kits, QIAamp DNA Micro Kit, random primers, and Omniscript reverse transcriptase were from Qiagen (Valencia, CA); and SYBR green dye was from SA Biosciences (Frederick, MD). Custom primers were designed by TIB MolBiol (Adelphia, NJ). The HEK293 cell line was obtained from ATCC (Manassas, VA), luciferase assay reagents were from Promega (Madison, WI), and other routine supplies and chemicals were from Fisher and Sigma.
Construction of tafazzin small hairpin RNA adenovirus. The small hairpin sequences recognize tafazzin coding regions 5=-CAGCT-GTGGAGATGCGGAA-3= Taz1 and 5=-AGAGGAATTCCAGCG-GCT-3= Taz2 with restriction endonuclease XhoI and SpeI sites added at each end to facilitate subcloning. The small hairpin RNA (shRNA) oligonucleotides and scrambled sequence 5=-CAGTCCAGCTAGCTC-TACT-3= were synthesized by TIB MolBiol. Equal amounts of the upper and lower oligonucleotide were annealed by boiling and cooled to make the double-stranded shRNA. This was subcloned into a shuttle vector (pSilencer adeno 1.0-CMV), and the insertion was confirmed by sequencing. The virus DNA containing the insertion was packaged inside HEK293 cells. The adenovirus was expanded and the virus concentration (expressed as viral particles per milliliter) was estimated by spectrophotometry following Ambion's protocol.
Neonatal cardiac myocyte culture. Neonatal ventricular myocytes (NVMs) were isolated from 1-to 2-day-old Sprague-Dawley rats from Charles River as we described previously (24) . They were placed on 6-well (1 million per well) or 12-well plates (0.5 million per well) in DMEM containing 10% FBS and incubated for 40 h. The medium was changed to serum-, glucose-, and pvruvate-free medium supplemented with insulin, transferrin, and selenium; glutamine (2 mM); penicillinstreptomycin; and bromodeoxyuridine (0.1 mM). The adenovirus was added, and samples were incubated for 48 h. When the cell size was measured, they were plated at a lower density (6-well plates, 2.5 ϫ 10 5 cells per well) to improve the visualization of each individual cell.
Semiquantitative and real-time RT-PCR.
Total RNA isolation from NVMs was performed as described previously (25) . RNA (2 g) was reverse-transcribed into cDNA in 20 l reaction buffer containing 1 unit reverse transcriptase, 2 g random primer, 0.5 mM dNTP, and 10 units RNasin at 37°C for 1 h. The reverse transcription mixture was denatured at 95°C for 10 min. For semiquantitative PCR, tafazzin was amplified with 0.5 M primers (upper, 5=-AGCACGGTGATTTTCT-GTCC-3=; and lower, 5=-GGCAAATGTGTGCCTGTATG-3=) in 20 l reaction volume containing 0.25 mM dNTP and 1 unit Taq DNA polymerase for 22 cycles. The PCR products were run on 2% agarose gel, and DNA bands were visualized by ethidium bromide staining. The gels were imaged by transillumination and DNA bands quantified with Density software corrected by GAPDH (upper, 5=-ATTCAACG-GCACAGTCAAGG-3=; and lower: 5=-TGGATGCAGGGATGAT-GTTC-3=), which was amplified for 18 cycles. Tafazzin mRNA levels were expressed as a percentage of control. For real-time PCR, 2 l of the products of the reverse transcription reaction were amplified using SYBR dye (SA Biosciences) along with the same primers (including tafazzin and GAPDH as normalizer) in a Roche LightCycler (v. 2) as we described previously (20) . Tafazzin mRNA levels were determined using the ⌬⌬Ct method as described by Winer et al. (51) and expressed as a percentage of control.
Phospholipid metabolic labeling. NVMs were placed on six-well plates (1 million cells per well). [ 32 P]phosphate (1 Ci/well) was added 24 h after the adenovirus, and the samples were incubated for 24 h. The cells were harvested for phospholipids and analyzed by one-dimensional TLC as we described previously (22) . After exposure to X-ray film, the cardiolipin bands were scanned, quantified, and expressed as a percentage of control (NVMs infected with a scrambled shRNA adenovirus).
ATP assay. Cells were lysed in 0.2% SDS, and ATP was measured with a kit from Sigma. ATP content was corrected by total protein, which was determined using a kit from Thermo Fisher with BSA as a standard. ATP content was expressed as relative light units per microgram protein.
Western blot analysis. Western blot analysis was performed as we described previously (23) using 50 g total cell extract protein.
Protein concentration was determined with the Coomassie protein assay kit using BSA as the standard.
Mitochondrial staining. At the end of the experiment, the cells were incubated with 200 nM MitoTracker red in the dark for 20 min. They were then washed with PBS and fixed in 37% formaldehyde for 30 min at room temperature in the dark. The cells were washed with PBS and counterstained with DAPI for 3 min and then washed and mounted. Five images were obtained from each field using fluorescence microscopy with red and blue filters and merged with SPOT software. The red fluorescence intensity representing mitochondrial density was quantified using MicroSuite software and expressed as fluorescent intensity per cell.
Mitochondrial DNA assay. Total DNA including mitochondrial DNA was isolated from NVMs using QIAamp DNA Micro Kit from Qiagen. Mitochondrial NADH dehydrogenase 1 (ND1) gene content was determined by real-time PCR, as described in Semiquantitative and real-time RT-PCR, with10 ng total DNA as the template using primers upper 5=-ATGGCCTTCCTCACCCTAGT-3= and lower 5=-AGAGGGCGTATGGGTTCTTT-3=. ND1 was normalized with genomic gene GAPDH using the same set of primers described in Semiquantitative and real-time RT-PCR.
Cardiac myocyte surface area. NVMs were plated onto laminincoated coverslips in six-well plates at a density of 0.25 million cells per well. After we treated them with the adenovirus, they were immunostained with a ␤-actin antibody and visualized with an FITCconjugated secondary antibody. The nuclei were counterstained by DAPI. Five images of each field were captured with fluorescence microscopy using DAPI and FITC filters and merged with SPOT software. The surface area (expressed as m 2 ) was measured with MicroSuite software.
[ Transfection and luciferase assay. NVMs were transfected by electroporation using a cuvette with a 2-mm gap (BTX, San Diego, CA) in 0.4 ml PBS buffer containing 0.1% glucose and 1 g Ϫ1818hBNPluc plasmid DNA per million cells. The cells were placed on 12-well plates and maintained in DMEM containing 10% FBS for 40 h. The medium was then changed to serum-, glucose-, and pvruvate-free DMEM; the shRNA adenovirus (100 vp/cell) was added; and the samples were maintained for 48 h. Finally, the cells were harvested for luciferase activity (23) , which represents human brain natriuretic peptide (hBNP) promoter activity and is expressed as fold increase vs. control (cells infected with a scrambled shRNA virus). The Ϫ1818hBNPluciferase construct (33) was graciously provided by Dr. M. C. LaPointe (Henry Ford Hospital, Detroit, MI).
Statistical analysis. Data are expressed as means Ϯ SE. Differences in mean values were analyzed by two-tailed t-test or one-way ANOVA using the Student-Newman-Keuls method for pairwise multiple comparisons. A value of P Ͻ 0.05 was considered significant.
RESULTS

Construction of tafazzin shRNA adenovirus.
To test the efficiency of our tafazzin shRNA adenovirus in knocking down tafazzin mRNA, we used doses ranging from 0.1 to 100 viral particles per myocyte (vp/cell) of two different constructs (Taz1 and Taz2). We found that 100 vp/cell gave the best results without affecting cell growth (Fig. 1A) . Some NVMs were killed and the others displayed cell abnormal morphology when treated with 800 vp/cell shRNA adenovirus (data not shown). Whereas both Taz1 and Taz2 significantly knocked down tafazzin mRNA, Taz1 reduced the expression by 70% compared with only 28% for Taz2 (Fig. 1B) . The internal control gene GAPDH was not affected by the shRNA adenovirus. Based on our findings, we used a dose of 100 vp/cell Taz1 shRNA adenovirus for all experiments.
Tafazzin knockdown decreases cardiolipin. Tafazzin mutation decreases cardiolipin content (18, 43, 48) . We then tested whether tafazzin knockdown in NVMs affects cardiolipin content and found that tafazzin knockdown significantly decreased cardiolipin in NVMs (Fig. 2) compared with scrambled con-trol, as determined by metabolic labeling and thin-layer chromatography analysis. In contrast, other phospholipids were not affected by tafazzin knockdown. Thus tafazzin knockdown in NVMs mimics cardiolipin deficiency in Barth syndrome.
Tafazzin knockdown decreases intracellular ATP. The primary function of the mitochondria is the production of ATP, which is critically important for maintaining the pumping function of the heart. ATP depletion has been associated with cardiomyopathy and heart failure (2, 3, 8, 36). Barth syndrome, which is characterized by DCM, causes metabolic decompensation and energy deficiency (12, 34, 56) . We infected NVMs with the tafazzin shRNA adenovirus for 48 h in a medium containing glutamine as the sole energy molecule and found that intracellular ATP was significantly reduced compared with cells infected with a scrambled shRNA adenovirus (Fig. 3) . This ATP must have come from the mitochondria, because glutamine must be metabolized by oxidative phosphorylation within the mitochondria to generate ATP (38) ; thus tafazzin knockdown decreases mitochondrial ATP production.
Tafazzin knockdown activates AMPK and increases mitochondrial density. AMPK has been postulated as the "fuel gauge" of the cell and is regulated by intracellular ATP (19) . It is activated by a decrease in the ATP-to-AMP ratio. One of the long-term responses to AMPK activation is an enhanced mitochondrial biogenesis (29) . We investigated the effects of tafazzin on AMPK activation and mitochondrial biogenesis and found that tafazzin knockdown dramatically increased AMPK phosphorylation (Fig. 4A ) compared with a scrambled virus control. As visualized by MitoTracker red (Fig. 4, B and  C) , the mitochondrial density (red stains) around the nucleus, which was stained in blue by DAPI, was significantly in- creased. The concentration of mitochondrial DNA is proportional to the number of mitochondria per cell (37) . An enhanced mitochondrial biogenesis was further confirmed by the increased ND1 gene content as assayed by real-time PCR (Fig.  4D) . These data suggest that decreased mitochondrial ATP production activates AMPK, which in turn enhances mitochondrial biogenesis.
Tafazzin knockdown causes cardiac myocyte hypertrophy. We next studied the effect of tafazzin knockdown on NVM hypertrophy. We found that tafazzin knockdown significantly increased NVM size compared with the SCR control (Fig. 5, A  and B) . Protein synthesis as represented by [ 3 H]leucine incorporation was also significantly increased (Fig. 5C) .
We also investigated whether tafazzin knockdown induces the hypertrophic marker gene, BNP expression. As shown in Fig. 6, A and B , tafazzin knockdown significantly increased the expression of BNP as determined by semiquantitative RT-PCR. The activation of BNP gene transcription was assayed by measuring a hBNP promoter coupled to a luciferase reporter gene. Tafazzin knockdown significantly increased BNP promoter activity compared with the scrambled virus control (Fig.  6C) . Thus tafazzin knockdown induced hypertrophy in NVMs.
DISCUSSION
Ablation or decreased expression of tafazzin has been shown to reduce cardiolipin in several types of cells and model systems (18, 43, 44, 47, 48, 53 ). Our current finding that tafazzin knockdown decreases cardiolipin in NVMs is consistent with previous cell studies. Cardiolipin deficiency due to tafazzin knockdown resulted in an impaired mitochondrial function (seen as reduced ATP production) as observed in yeast (34) , as well as the energy depletion seen in patients with Barth syndrome.
The depletion of ATP in cardiac myocytes has several detrimental effects, including contractile dysfunction, hypertrophy, and cell death. Acutely, ATP depletion switches on the ATP-producing catabolic pathways such as fatty acid oxidation and glycolysis and switches off the ATP-consuming anabolic pathways such as lipogenesis and glyconeogenesis (41) . One long-term response to ATP depletion is enhanced mitochondrial biogenesis, which is mediated by the activation of the "fuel gauge" AMPK (19). Jager et al. (29) reported that AMPK directly phosphorylates and activates PGC-1␣, the key regulator of mitochondrial biogenesis. During strength and endurance training, more ATP is consumed, and this coincides with increased mitochondrial volume in the muscle (40) . Our data showing that tafazzin knockdown increased mitochondrial density in NVMs support the concept that ATP depletion enhances mitochondrial biogenesis. This is also consistent with the increased number of mitochondria found in the lymphocytes of patients with Barth syndrome (55) .
Our data show that tafazzin knockdown causes NVM hypertrophy as indicated by increased cell surface area, protein synthesis, and expression of the hypertrophic marker gene BNP. Several factors may be involved in the cardiomyocyte hypertrophy induced by tafazzin knockdown. First, increased mitochondrial density contributes to increased NVM volume because cardiac myocytes have a very high mitochondrial density (16) , occupying about 40% of the cytoplasmic volume in mice (13) . Previous studies also showed that mitochondrial volume and density increase in proportion to increased cell volume (26, 28, 46) . Second, the depletion of ATP may directly cause cardiomyocyte hypertrophy, since ATP deficiency reduces contractile efficiency and this leads to compensatory hypertrophy. Finally, as we observed in yeast (9) , impaired mitochondrial function due to a deletion of tafazzin causes increased oxidative stress that contributes to cardiomyocyte hypertrophy (1, 6, 9, 10, 27, 52). Without conducting pressure loading, we could not differentiate between eccentric (increased length-to-width ratio) and concentric hypertrophy (increased cross-sectional area); however, eccentric cardiomyocyte hypertrophy is characteristic of DCM based on pre- vious studies (14, 15, 20) . The fact that tafazzin knockdown induces hypertrophy of NVMs is relevant in vivo because cardiac myocytes occupy 75% of the myocardial structural space even though they constitute only one third of the cell population (50) . Undoubtedly, cardiomyocyte hypertrophy is a major factor in cardiomyopathy.
In summary, our data indicate that tafazzin knockdown causes hypertrophy in NVMs. Decreased tafazzin expression lowers cardiolipin in NVMs, and this in turn blunts ATP production by the mitochondria. The decrease in ATP activates AMPK and enhances mitochondrial biogenesis, which contributes to the increased volume of NVMs. We believe our findings establish a link between tafazzin mutation and cardiomyocyte hypertrophy.
